Regulatory T Cells in GVHD Therapy
| Autor: | Xiaoming Feng, Ming-Yang Wang, Mingzhe Han, Xiu-Hua Su, Wen-Wen Guo, Erlie Jiang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Adoptive cell transfer chronic graft versus host disease medicine.medical_treatment Immunology Graft vs Host Disease Graft vs Leukemia Effect chemical and pharmacologic phenomena Hematopoietic stem cell transplantation Review Immunotherapy Adoptive T-Lymphocytes Regulatory regulatory T cells Immune tolerance 03 medical and health sciences Therapeutic approach 0302 clinical medicine Immune system immune system diseases medicine Immunology and Allergy Animals Humans Cell Proliferation Immunosuppression Therapy business.industry Peripheral Tolerance acute graft versus host disease Models Immunological Immunosuppression Forkhead Transcription Factors hemic and immune systems RC581-607 medicine.disease Adoptive Transfer Tissue Donors Clinical trial 030104 developmental biology Graft-versus-host disease surgical procedures operative adoptive cellular therapy 030220 oncology & carcinogenesis hematopoietic stem cell transplantation Immunologic diseases. Allergy business Immunosuppressive Agents |
| Zdroj: | Frontiers in Immunology, Vol 12 (2021) Frontiers in Immunology |
| ISSN: | 1664-3224 |
| DOI: | 10.3389/fimmu.2021.697854/full |
| Popis: | Graftversushost disease (GVHD) is a common complication and the leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Pharmacological immunosuppression used in GVHD prophylaxis and treatment lacks specificity and can increase the likelihood of infection and relapse. Regulatory T lymphocytes (Tregs) play a vital role in restraining excessive immune responses and inducing peripheral immune tolerance. In particular, clinical trials have demonstrated that Tregs can prevent and treat GVHD, without increasing the risk of relapse and infection. Hence, adoptive transfer of Tregs to control GVHD using their immunosuppressive properties represents a promising therapeutic approach. To optimally apply Tregs for control of GVHD, a thorough understanding of their biology is necessary. In this review, we describe the biological characteristics of Tregs, including how the stability of FOXP3 expression can be maintained. We will also discuss the mechanisms underlying Tregs-mediated modulation of GVHD and approaches to effectively increase Tregs’ numbers. Finally, we will examine the developing trends in the use of Tregs for clinical therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|